3–35 HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study

Estrogen receptor (ER) and progesterone

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

✍ Richard M. Elledge; Stephanie Green; Reginald Pugh; D. Craig Allred; Gary M. Cla 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 133 KB 👁 2 views

Results of estrogen receptor (ER) and progesterone receptor (PgR) ligand-binding assays (LBAs) are strongly correlated with ER and PgR by immuno-histochemistry (IHC). To investigate whether ER and PgR by IHC are also strongly correlated with tamoxifen response, time to treatment failure (TTF) and ov